NW Bio is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side effects of chemotherapy drugs. NW Bio’s proprietary manufacturing technology enables the Company to produce its personalized vaccine in an efficient, cost-effective manner. The Company has a broad platform technology for DCVax dendritic cell-based vaccines. The Company’s lead product, DCVax-L, is currently in a 348-patient Phase III trial for patients with newly diagnosed Glioblastoma multiforme (GBM), the most aggressive and lethal brain cancer. The Company’s second product, DCVax-Direct, is currently in a 60-patient Phase I/II trial for direct injection into all types of inoperable solid tumor cancers. The Company has also conducted a Phase I/II trial with DCVax for late stage ovarian cancer together with the University of Pennsylvania. The Company previously received clearance from the FDA for a 612-patient Phase III trial with its third product, DCVax-Prostate, for late stage prostate cancer.

Research Grants show all

NIH5

Publications show all

Northwest Biotherapeutics has published 33 articles.

Patents show all

138Applications67Issued

Clinical Trials show all

2Phase 1/Phase 22Phase 31N/A1Phase 11Phase 2

SEC Filings show all

8-K15010-Q4510-K15D3S-11

Private Funding Events

DateOfferedSoldType
2010-12-09$395,000$395,000Equity, Debt, Option to Acquire
2006-04-17UnknownUnknownOther (Paper Filing)

Key Executives

  • Alton L. Boynton
    Executive Officer
  • Linda F. Powers
    Director
  • Robert Farmer
    Director